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In the last decade, Nigeria has scaled up the antiretroviral 
program for people living with HIV. The number of 
people accessing antiretroviral therapies (ARTs) rose from 
10,000 (2002) to 300,000 (2010), especially through the U.S 
President’s Emergency Plan for AIDS Relief.[1] Our hospital 
was activated in August 2008 to provide ART services in south-
eastern Nigeria. Despite this free treatment, it is surprising 
that many patients still dropped out of the various programs 
at this facility. Rates of the loss to follow-up (LTFU) in 
resource-limited settings such as ours reported in the literature 
range from 16% to 40%.[2-4] Onoka et al. studied HIV programs 
in South-eastern Nigeria and reported LTFU rate between 11% 
and 32.8%.[5]
Researchers have shown that LTFU among HIV-infected patients 
in resource-limited settings is significantly associated with 
being male, baseline CD4 count <200/μL, age <35 years and 
Predictors of Loss to Follow‑up Among HIV‑infected 
Patients in a Rural South‑Eastern Nigeria Hospital: 
A 5‑year Retrospective Cohort Study
Eguzo KN, Lawal AK1, Umezurike CC2, Eseigbe CE3
Department of Academic Family Medicine, University of Saskatchewan, 1College of Pharmacy and Nutrition, University of 
Saskatchewan, Saskatoon, Canada, Departments of 2Obstetrics and Gynecology and 3Laboratory Services, Nigerian Christian 
Hospital, Nlagu, Nigeria
Abstract
Background: Patient attrition has been a challenge in managing HIV programs in 
resource‑limited settings. Aim: This study reviews the predictors of loss to follow‑up (LTFU) in 
our hospital and suggests the best practices for dealing with the issue. Subjects and Methods: 
A 5‑year retrospective cohort study of 1256 HIV‑infected patients. Baseline CD4 counts, age, 
gender, year of enrolment, and antiretroviral therapy combination regimen were considered 
in this study. Kaplan–Meier models were used to estimate the univariate time‑to‑LTFU and 
Cox proportional hazards models to identify the multivariate predictors of LTFU. Results: 
Twenty‑four percent (23.9% [301/1256]) of patients were lost to follow‑up. Baseline CD4 
count, year of enrolment, and drug combination were significant predictors of LTFU. Patients 
enrolled earlier (2008/2009) were twice as likely to be LTFU compared with those enrolled 
later (2010–2013). Gender and age did not significantly predict LTFU nor confound other 
predictors. Conclusion: The program showed higher LTFU rates than most studies in Nigeria 
and Africa, maybe due to difficulties with the access to the hospital and possible treatment 
fatigue. This study recommends the provision of transportation subsidies and proactive patient 
follow‑up with “peer‑tracking” to reduce LTFU among HIV infected patients, especially in 
resource‑limited settings.
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with stavudine containing first line regimen.[2] Few studies have 
been conducted to research into the predictors of LTFU in this 
region of Nigeria. Onoka et al. reported that LTFU for patients 
in South-eastern Nigeria was more likely for males, patients 
with CD4 count ≤200/μL and enrolees of programmes in public 
hospitals.[5] The follow-up period for this particular study was rather 
short (median 14 months), and did not consider the differences, 
based on treatment regimens throughout the follow-up time.
LTFU has been shown to contribute to poorer health outcome 
for patients and constitutes resource wastage, as well as the 
promotion of HIV drug resistance.[2,5] Research, however, has 
not differentiated LTFU rates between patients on ART and 
non-ART. Also, the rate of LTFU could be utilized as an index 
of program effectiveness with respect to patient tracking.[6] 
This study aims to identify the predictors of LTFU in a rural 
hospital, and to highlight best practices in improving patient 
retention in similar settings.
Subjects and Methods
Study setting and participants
This study was conducted at Nigerian Christian Hospital (NCH), 
Aba‑Nigeria; a rural 110‑bed faith‑based hospital affiliated 
with the Churches of Christ and International Health 
Care Foundation. Since August 2008, more than 3000 
HIV-infected people have been enrolled in its program. 
This program offers the voluntary counselling and testing, 
prevention-of-mother-to-child-transmission, pediatric 
and non-pediatric ARTs, as well as immunology services. 
Currently, there are about 2000 clients on treatment, and about 
40 clients are seen each day in clinic. The majority of patients 
enrolled in the program were recruited through antenatal 
care, voluntary testing, referral and in-patient hospitalization. 
A team of doctors, nurses, community health officers as well 
as monitoring and evaluation staff ensured patient follow-up 
and tracking of appointments. The hospital also offers specialist 
services in surgery, ophthalmology, oncology, internal 
medicine as well as obstetrics and gynaecology.[7]
According to the NCH treatment protocol, patients were 
considered eligible for ART if they were in the WHO clinical 
Stage 3 or 4 irrespective of CD4 cell count; if they were 
pregnant irrespective of CD4 count, and if they had a CD4+ cell 
count ≤350 cells/μL. Details of other treatment criteria were per 
the National and WHO guidelines.[1,8] Follow-up appointments 
ranged from fortnightly to quarterly, depending on the 
progression of the clinical disease, adherence profile, and 
prevailing circumstance. They were monitored for adherence 
and retention through home visits, frequent phone calls as 
well as attendance at support group meetings. Monitoring 
was conducted through the  IQ Care software (Futures Group, 
Washington D.C, USA).
This research is a retrospective cohort study of HIV patients 
aged 15 years or older who were enrolled at the NCH between 
August 1, 2008, and October 25, 2013. The inclusion criteria 
were; (1) subjects must be HIV positive, ≥15 years of age 
and (2) enrolled at NCH. It excluded the patients who were 
transferred to other treatment facilities during the study period. 
Approval for the study was obtained from the Board of NCH. 
Patient confidentiality was maintained by using anonymized 
data extracted from the database.
Treatment, monitoring and endpoints
NCH program uses Truvada and Combivir based Highly 
Active Antiretroviral Therapy. First line treatment includes 
a combination of lamivudine-3TC and zidovudine (ZDV) 
(Combivir), with either nevirapine (NVP), or efavirenz (EFV). 
Truvada® (emtricitabine [FTC]/tenofovir [TDV]) with either 
NVP or EFV is also a first line. Regimen choice was based 
on baseline CD4 count, pregnancy status, tuberculosis 
co-infection, and previous ARTs exposure. Co-trimoxazole 
prophylaxis (960 mg q.d.) was provided to patients with 
CD4 ≤400 cells/μL. Following ART initiation, patients were 
followed up for 2 weeks to monitor for drug reactions and 
assess adherence. Subsequently, ARTs were dispensed on 
a monthly basis. With consistent adherence and follow-up, 
patients who were considered stable were given 2-monthly 
appointment schedules. Second line therapy was provided 
to clients who had clinical, or virologic failure on fi rst‑
line therapy. The 2nd line therapy included a combination 
of lopinavir/ritonavir (Kaletra®, Aluvia®-ALV) with either 
Truvada® or Combivir®. For the purpose of this research, 
these combinations were categorized as Combivir-based 
first line (3TC/ZDV with EFV or NVP); Truvada‑based first 
line (TDV/FTC with EFV or NVP); Combivir-based second 
line (3TC/ZDV with ALV), and Truvada-based second 
line (TDV/FTC with ALV).
This study considered the immunologic classification of the 
disease using baseline CD4 count, based on WHO criteria.[9] 
Patients were classified as follows: CD4 ≥ 500/μL – “not 
significant disease;” 350–499/μL – “mild disease;” 
200–349/μL – “advanced disease” and <200/μL – “severe 
disease.” Age at enrolment was further classified as 15–24 
years; 35–44 years, and ≥45 years; in line with the classification 
used in peer-reviewed literature.[10-12] Table 1 shows the 
baseline characteristics of patients included in the study.
LTFU, the main endpoint in this study, was defined as a patient 
who missed an appointment for more than 6 months after the 
last visit and could not be traced until the end of the study 
period.[13] The date of the last visit was taken as the date of 
the event. Patients were considered censored, if dead (based 
on reported date or last visit date) or if they were alive at the 
end of the study period (October 25, 2013).
Statistical analysis
The dependent variable in this study is the patient’s status, 
categorized as either dead, alive, transferred, or LTFU. 
Univariable Kaplan–Meier analysis was performed at  =0.05 
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level to determine the independent predictors of LTFU using 
sex, year of enrolment, age group, baseline WHO CD4 category, 
treatment program, and drug combination. Significant baseline 
variables in the univariable analysis were included in the final 
multivariable model. All other analyses were two-sided, and 
level of significance was set at P < 0.05. Statistical analysis 
was done using SAS version 9.3. (SAS Institute Inc., Cary, 
NC, USA). Kaplan–Meier method was used to estimate the 
retention rates after ART initiation, and log-rank tests to 
compare the survival curves. Cox proportional hazards models 
were used to identify the predictors of LTFU and calculate 
the hazard ratios (HRs). The survival time was calculated in 
months using the time interval between the date of enrolment 
and (1) the date of the event (LTFU) or (2) date of censoring.
Results
A total of 1256 patients were eligible for this study, comprising 
68.3% (858/1256) females and 31.7% (398/1256) males. 
The median age in the study was 37 years; males 41 years 
and females 35 years, respectively. 23.9% (307/1256) 
patients were lost to follow-up during the 5-year period 
after enrolment in the program while 76% (955/1256) 
were censored. Table 2 shows the baseline characteristics 
of study population. The median LTFU time for non-ART 
clients was 1-month while those on ART could be not 
estimated as the majority of the observations were censored. 
In total, those LTFU comprised 36.8% (107/307) males 
and 64.5% (194/307) females. Based on age, those LTFU 
comprised 5.6% (17/307) aged 15–24; 38.2% (115/307) aged 
25–34; 36.2% (109/307) aged 25–44, and 19.9% (60/307) 
aged above 45 years. In terms of the year of enrolment, 
the highest proportion of patients LTFU (32.9% [99/307]) 
was recorded in 2009. LTFU was most common among the 
patients with baseline CD4 < 200/μL (82.4% [253/307]) 
and lowest among those with baseline CD4 counts of 
200–349/ml, 3.3% (10/307). LTFU was more prominent 
among patients taking Truvada-based first line agents 
28.7% (88/307) compared with 18.9% (58/307) for those on 
the Combivir‑based first line. At the end of the study period, 
955 patients were censored comprising 10.2% (97/955) 
deaths and 89.8% (858/955) alive.
Based on the univariable analysis, baseline CD4 count [Figure 1], 
year of enrolment [Figure 2], drug combination [Figure 3], and 
treatment program (ART, non-ART) [Figure 4] were significant 
predictors of LTFU. Gender and age did not significantly predict 
LTFU and did not interact/confound the other predictors. 
Table 3 shows the univariable and multivariable analyses.
Discussion
This 5-year retrospective cohort study of people living 
with HIV/AIDS sheds light on the concept of LTFU and its 
determinants in a program administered in a rural Nigerian 
hospital. Previous studies found that the male patients were 
more likely to suffer attrition; our study did not find any 
significant difference in LTFU rates based on age and gender, 
and these were neither confounding nor interacting with any 
other predictors considered in the study. However, we found 
that the patients who were enrolled earlier in the program (2008 
and 2009) were at least twice more likely than those enrolled 
later (2010–2013) to be lost to follow-up. Hazard of LTFU 
for patients enrolled in 2008 was 3 times higher than 2013 
enrolees (HR 3.1 95% confidence interval [CI] 1.16–8.17; 
P = 0.02), while the hazard for those enrolled in 2009 was 
2 times higher (HR 2.69 95% CI 1.05–6.88, P = 0.04). Baseline 
CD4 counts and drug combinations were not found to be 
significant predictors of LTFU in this study.
Table 1: Baseline characteristics and the proportion of 







Male 398 107 (35.6)
Female 858 194 (64.5)
Enrolment year
2008 156 46 (15.3)
2009 341 99 (32.9)
2010 173 38 (12.6)
2011 255 52 (17.3)
2012 216 56 (18.6)
2013 115 10 (3.3)
Care program
ART 1045 157 (52.2)
Non‑ART 190 133 (44.2)
Age group (years)
15‑24 51 17 (5.65)
25‑34 422 115 (38.2)
35‑44 508 109 (36.2)
45+ 275 60 (19.9)
Baseline CD4 staging (cells/μL)
>500 183 73 (24.3)
350‑499 174 40 (13.3)
200‑349 325 54 (17.9)
<200 594 134 (44.5)
200‑349 156 10 (3.3)
<200 594 253 (84.1)
Drug regimen
Combivir‑based first line 383 58 (19.3)
Truvada‑based first line 547 88 (29.2)
Combivir‑based second line 66 6 (2)
Truvada‑based second line 53 4 (1.3)
LTFU: Loss to follow-up, NCH: Nigerian Christian Hospital, ART: Antiretroviral therapy
Table 2: Last know status of HIV patients NCH included in 
the study
Last known status Number (%)
Dead 97 (7.7%)
Alive 858 (68.3%)
NCH: Nigerian Christian Hospital
Eguzo, et al.: Loss to follow up in South‑Eastern Nigeria
376 Annals of Medical and Health Sciences Research | Nov-Dec 2015 | Vol 5 | Issue 6 |
Overall, our LTFU rate was more than twice the value reported 
by Onoka et al., who compared patient attrition between public 
and private institutions.[5] Several factors could be responsible 
for this; the functioning of the hospital was adversely affected 
by insecurity between 2009 and 2012 due to kidnapping 
that was rampant in our community. In addition, the access 
road to the hospital has been in a state of disrepair for more 
than 3 years. The difficulty in accessing treatment due to 
transportation difficulties could have discouraged a good 
number of our patients.
Although the adjusted hazards for patients on ART compared 
to non‑ART patient was not significant, the univariable analysis 
may help to draw our attention to the concept of “treatment 
fatigue” among HIV patients. Treatment fatigue describes the 
psychological exhaustion of patients with chronic diseases, 
who have to take numerous pills over a long time. Further 
research should be conducted to explore this concept and its 
impact on rates of LTFU among HIV patients.
Toward reduction of LTFU among HIV patients: Review of 
best practices.
Understanding the causes of patient attrition and improving 
retention in care is challenging in resource-limited-settings.[14] 
Evidence shows that improved documentation can impact 




Figure 4: Kaplan–Meier curves for loss to follow‑up based on year 
of enrolment
Figure 2: Kaplan–Meier curves for loss to follow‑up based on baseline 
CD4 class
CD4 stage 1 (≥500 cells/μL)
CD4 stage 2 (350‑499 cells/μL)
CD4 stage 3 (200‑349 cells/μL)
CD4 stage 4 (<200 cells/μL)
Log rank P<0.001
Figure 3: Kaplan–Meier curves for loss to follow‑up based on drug 
combination regimen
Combination1 (Combivir 1st line)
Combination 2 (Truvada 1st line)
Combination 3 (Combivir 2nd line)
Combination 4 (Truvada 2nd line)
Log rank P=0.09
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patient attrition. Some patients have been known to be 
lost to follow-up in one facility, only to end up in another 
facility as clients.[14] We think it is necessary to improve local 
documentation and share medical records (to some extent) for 
patients receiving ART. This can be achieved through greater 
collaboration among treatment providers in a geographic area. 
Nigeria has moved toward this by streamlining the coordination 
of treatment providers under two broad programs; this makes 
records sharing easy.
Also, the model of treatment programs is crucial in improving 
patient retention. Although Geng et al. found that LTFU was 
about 8-fold higher in larger, centralized treatment centers 
compared to smaller centers. This may not be unconnected 
with the difficulty in monitoring a large pool of patients, 
especially in resource-limited settings. Although there is no 
definition of “large centers,” our experience in NCH suggests 
that the programs with more than 2000 clients may be more 
prone to higher LTFU rates. It may be important to limit the 
size of individual treatment programs to below 2000. This 
will lead to the activation of more treatment sites that will be 
closer to the clients’ communities, thus improving tracking. It 
may also handle the challenge of tracking non-ART patients, 
who are historically more likely to be lost to follow-up, even 
in NCH.[14] Retention is also higher for programs with peer 
group support (such as the support group meetings at NCH) 
and outreach services (such as home visits).[14]
Meanwhile, many patients experience the transportation 
difficulties, maybe due to the poor condition of roads (like 
in NCH), or poverty. Travel times longer than 2 hours have 
been associated with double LTFU rates.[15] Emenyonu 
et al. found that the patients who received transportation 
subsidy were significantly less likely to be LTFU.[16] This 
suggests that the programs may benefit from some form 
of transportation subsidy. Evidence also suggests that 
the patients with strong social support are less likely to 
abandon treatment.[14] NCH has a vibrant support group 
for our clients, and this improves “peer-tracking.” Etienne 
et al. reviewed the treatment programs in 27 low-income 
countries, and found that sites with “proactive follow-up” 
models, such as home visits, had lower rates of LTFU.[17] 
These suggestions are not exhaustive, but only go to show 
some approaches that are successful. With the rapid 
penetration of mobile technology in Africa, we encourage 
program managers to explore its use in patient tracking 
and retention.
Study limitations
This study is limited because of the sampling strategy. 
Including all eligible patients provided a skewed sample that 
made it difficult to explore some statistical quantities. We 
did not explore other variables that could influence patient 
retention such as the effect of travel time, social support, and 
home visits on LTFU at NCH and inability to capture the 
washout period before switching to second-line antiretroviral 
agents made it difficult to draw comparisons between levels 
of therapy.
Conclusion
The study was conducted to identify the determinants of 
LTFU in a retrospective cohort of HIV patients followed for 
60 months. We have shown that people enrolled earlier in the 
program are more likely to drop out of treatment, thus helping 
program managers to better focus their interventions on LTFU. 
Although an observed difference was identified for patients on 
ART compared to non-ART patients, this difference was not 
significant when other factors were considered in the adjusted 
model. Further research is needed to explore the concept of 
“treatment fatigue” as a factor in LTFU for patients receiving 
HIV treatment. HIV program managers are also encouraged 
to intensify the follow-up strategies for patients on ART 
medications in their programs.
Table 3: HRs of LTFU according to predictors for HIV patients in NCH
Variable Unadjusted (univariable) Adjusted (multivariable)
HR (95% CI) P HR (95% CI) P
Baseline CD4 staging (vs. >500 cells)
<200 0.60 (0.45‑0.79) <0.001 1.00 (0.62‑1.62) 0.99
200‑349 0.54 (0.37‑0.80) <0.001 0.42 (0.21‑0.85) 0.02
350‑499 0.40 (0.27‑0.55) <0.001 0.75 (0.44‑1.27) 0.28
Drug combination
Truvada versus Combivir first line 0.95 (0.68‑1.33) 0.78 0.82 (0.58‑1.16) 0.26
Truvada versus Combivir second line 0.90 (0.25‑3.20) 0.88 0.95 (0.27‑3.34) 0.94
Enrolment year (vs. 2008)
2009 1.02 (0.72‑1.45) 0.89 0.87 (0.56‑1.36) 0.55
2010 0.76 (0.50‑1.17) 0.30 0.53 (0.30‑0.96) 0.03
2011 0.74 (0.50‑1.11) 0.14 0.41 (0.23‑0.73) <0.001
2012 1.06 (0.71‑1.57) 0.76 0.66 (0.58‑1.15) 0.14
2013 0.44 (0.22‑0.87) 0.02 0.33 (0.12‑0.86) 0.02
NCH: Nigerian Christian Hospital, LTFU: Loss to follow‑up, HRs: Hazard ratios, CI: Confidence interval
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